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PCPAAims: Piperazinic derivatives have therapeutic potential by acting as analgesic, antidepressant-like, anticonvulsant
and antipsychotic in preclinical studies. In order to develop new drugs to treat mental disorders, we designed and
synthesized the 4-(1-phenyl-1H-pyrazol-4-ylmethyl)-piperazine-1-carboxylic acid ethyl ester (PPMP), a new
piperazine derivative with putative activities on central nervous system that seems to involve serotonergic system.
Materials and methods: In order to investigate the antidepressant-like activity of PPMP, mice were treated acutely
and tested in the forced swimming test (FST) and tail suspension test. Pretreatment with the 5-HT synthesis
inhibitor p-chlorophenylalanine (PCPA, 100 mg/kg, i.p., 4 days), and the non-selective blocker of catecholamine
synthesis α-methyl para-tyrosine (AMPT, 100 mg/kg, i.p.) were used to assay the involvement of serotonergic
and catecholaminergic systems. “Ex vivo” monoamine oxidase (MAO) enzymatic assay and quantiﬁcation
of hippocampal level of brain derived neurotrophic factor (BDNF) were carried out.
Key ﬁndings: PPMP reduced the immobility time in both tests. PCPA or AMPT (100 mg/kg, i.p.) pretreatment
blocked the effects of PPMP, thereby suggesting the involvement of serotonergic and catecholaminergic
systems in the antidepressant-like effect of PPMP. PPMP did not inhibit the activity of MAO. Moreover, after
14 days of treatment, PPMP 15 mg/kg/day induced antidepressant-like effect and increased hippocampal level of
BDNF. None of the treatments in this study altered the locomotor activity in the open ﬁeld test.
Signiﬁcance: In conclusion, PPMP demonstrates antidepressant-like effect that involve both serotonergic and
catecholaminergic systems without inhibition of MAO activity. PPMP administration increased the hippocampal
levels of BDNF.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Depressive disorders are among the most prevalent psychiatric
illness, affecting approximately 16% of the population [1]. Lifetime preva-
lence of major depressive disorders has estimate that ranged from 1.0%
(Czech Republic) to 16.9% (United States), with midpoints at 8.3%
(Canada) and 9.0% (Chile). The 12-month prevalence estimates
ranged from 0.3% (Czech Republic) to 10% (United States), with mid-
points at 4.5% (Mexico) and 5.2% (West Germany) [48].ia de Produtos Naturais, — Sala
001-970 Goiânia, GO, Brazil.Although the neuropathophysiology of major depressive disorders
remains unclear, the monoaminergic hypothesis of depression is still
valid. According to this hypothesis, the depletion of serotonin, noradren-
aline, and dopamine in the central nervous system (CNS) is associated
with depression. The antidepressant drugs, such as tricyclic antidepres-
sants, selective serotonin reuptake inhibitors and monoamine oxidase
inhibitors exert their therapeutic effects by increasing the availability of
these monoamines [2].
As this hypothesis could not explain fully the depression complexity
and the delay in therapeutic effect of antidepressant drugs, other
complementary theories such as the neurotrophic hypothesis, which
postulates that low levels of neurotrophic factors mainly the brain-
derived neurotrophic factor (BDNF) is associated with depression.
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factor [3,4].
Previous preclinical activities (analgesic [5], antidepressant-like
[6–8], anticonvulsant [9], antipsychotic [10], antiarrhythmic [11],
antiplasmodial and leishmanicidal [12]) of piperazinic derivatives
are indicators of its therapeutic potential. In order to develop new
drugs to treat mental disorders, we designed and synthesized 4-(1-
phenyl-1H-pyrazol-4-ylmethyl)-piperazine-1-carboxylic acid ethyl
ester (PPMP), a new piperazine derivative with putative activities
on CNS. In the previous study, PPMP showed anxiolytic-like activity
in different animal models without altering motor performance. This
activity seems to involve serotonergic system but not benzodiazepine
receptors [13].
The present study sought to evaluate antidepressant-like effect of
PPMP and the possible contribution of serotonergic and catecholaminer-
gic systems. The activity of monoamine oxidase (MAO), hippocampal
levels of BDNF and acute toxicity of this compound were investigated.
2. Material and methods
2.1. Animals
Experiments were conducted using 300 male Swiss mice, weighing
25–35 g (3–4 months old), provided by the Central Animal House
of Federal University of Goiás (Universidade Federal de Goiás — UFG).
Animals were maintained at a constant room temperature of 21–23 °C
under a 12:12 h light:dark cycle (lights on at 7:00 h) with free access
to water and food. Mice were housed in standard laboratory cages in
groups of 16–20. All experimental procedureswere carried out between
09:00 and 16:00 h. All efforts were made to minimize animal suffering
and to reduce the number of animals used. All studies were performed
in accordance with the Guide for the Care and Use of Laboratory Animals
as published by the National Institutes of Health. The experimental proto-
cols were approved by the Ethics Commission of the UFG (n° 104/11) in
compliance with the Brazilian legislation (#11.794—10/08/2008).
2.2. Drugs
PPMPwas synthesized in the Laboratório de Química Farmacêutica e
Medicinal (LQFM— Faculty of Pharmacy, Federal University of Goiás)
as described by Brito et al. [13]. Clorgyline, p-chlorophenylalanine
(PCPA), α-methyl para-tyrosine (AMPT), tyramine, vanillic acid, 4-
aminoantipyrine, peroxidase, polyoxyethylenesorbitan monooleate
(Tween 80®) were purchased from Sigma–Aldrich (Brazil). Imipramine
(Trofanil® — Novartis, Brazil), ﬂuoxetine (EMS, Brazil), tranylcypromine
(Parnate® — GlaxoSmithKline, Brazil) were also used. PPMP, PCPA,
AMPT were suspended in 2% Tween 80. Imipramine, ﬂuoxetine,
tranylcypromine, clorgylinewere dissolved in a 0.9w/v % NaCl solution.
The other drugs were dissolved in the potassium phosphate buffer. The
treatment doses were selected from previous studies [13,36–38].
2.3. Behavioral tests
2.3.1. Open ﬁeld test (OFT)
The apparatus consisted of a circular wooden arena measuring
36 (diameter) × 20 cm (height), with the bottom divided into eight
squares of equal area. For openﬁeld test, animalswere placed individually
at the center of the open ﬁeld arena to freely explore it for 5 min [14].
During this time, the locomotor activity: deﬁned as the number of total
squares crossed/5 min was videotaped. The arena was cleaned with
a 10% ethanol solution after each exposure of animal.
2.3.2. Forced swimming test (FST)
Each mouse was placed individually in a plastic cylinder (diameter
18 cm, height 42 cm) ﬁlled with water (25 ± 1 °C) at a height of
30 cm. Each session was recorded by a videocamera. The immobilitytime (ﬂoating while making only the movements necessary to keep
the head above the water surface level) was scored during 6 min [15].2.3.3. Tail suspension test (TST)
In a soundproof experimental room, mice were suspended indi-
vidually by the tail at the height of 74 cm above the ﬂoor and afﬁxed
with adhesive tape placed approximately 1–2 cm from the tip of the
tail. The immobility time was recorded for 6 min [16].2.3.4. Acute treatment with PPMP
In order to investigate the acute effects of PPMPon locomotor activity
and antidepressant-like effect, male mice were treated orally with this
compound at ﬁve different doses (3.7, 7.5, 15, 30 and 60 mg/kg) 1 h
prior to OFT and FST. TST was performed in independent groups of
male mice, 1 h after the administration of PPMP at the doses of 3.7, 7.5
and 15 mg/kg. Imipramine 30 mg/kg was used as a positive control in
these protocols.2.3.5. Role of the serotonergic and catecholaminergic systems in
antidepressant-like effect of PPMP
In order to investigate a possible contribution of 5-HT (serotonin) sys-
tem in the antidepressant-like effect of PPMP, animals were pretreated
(i.p)with PCPA (100mg/kg, a tryptophan hydroxylase inhibitor) or vehi-
cle (2% Tween 80), once a day, for 4 consecutive days in a separate series
of experiments. Then, 1 h after the last PCPA or saline injection, animals
were treated (p.o.) with PPMP 15 mg/kg or vehicle (2% Tween 80) and
tested in the OFT and FST as described earlier.
In order to study a possible contribution of catecholaminergic
system in the antidepressant-like effect of PPMP, animals were
pretreated (i.p.) with AMPT (100 mg/kg, a tyrosine hydroxylase
inhibitor) or vehicle (2% Tween 80). Then, 4 h later, animals were
treated orally with PPMP 15 mg/kg or vehicle (2% Tween 80) and
tested in the OFT and FST 1 h later, as described earlier.2.3.6. Ex vivo MAO assay
In order to analyze a possible inhibition of MAO activity, animals
were treated (p.o.) with PPMP 15 mg/kg, tranylcypromine 15 mg/kg
p.o. (non-speciﬁc MAO inhibitor) and clorgyline 15 mg/kg p.o. (MAO-A
inhibitor). After 1 h of treatments, animals were tested in the FST prior
to brain dissection.
The dissected brains were washed in ice-cold potassium phosphate
buffer (0.2 M, pH 7.6), and stored at−20 °C until MAO assays. Brains
were thawed and homogenized (Turrax®) in 20 vol. of 0.32 M sucrose
solution in potassiumphosphate buffer. Homogenateswere centrifuged
(1200×g, 7min, 4 °C). The supernatantswere collected and recentrifuged
(12,500 ×g, 15 min, 4 °C). The pellets obtained were centrifuged
(12,500 ×g, 15 min, 4 °C) in 0.32 M sucrose solution in potassium
phosphate buffer. The crude mitochondrial pellets were resuspended in
1 ml of 3.6 mM KCl solution in potassium phosphate buffer. Protein
contents of crude mitochondrial solution were measured by the
Bradford's method [17] using bovine serum albumin as standard. At the
time of use, protein concentration was adjusted with phosphate buffer
(0.2 M; pH 7.6) to 0.2 mg/mL. The continuous peroxidase-linked photo-
metric assay was carried out in the 96-well microtiter format modiﬁed
from Holt et al. [18] and Stafford et al. [19]. Each test well contained
120 μL amino substrate (2.5mM tyramine) in potassium phosphate buff-
er, 40 μL chromogenic solution (2 mM vanillic acid, 1 mM 4-
aminoantipyrine, 8 U/mL peroxidase in potassium phosphate buffer),
40 μL enzyme (rat liver homogenate) and 40 μL of sample. Background
wells contained potassium phosphate buffer (0.2 M, pH 7.6) in place of
chromogenic solution. The plate was incubated at 37 °C during 30 min
and read at 498 nm. MAO activity was expressed as a percentage of
absorbance of the vehicle-treated control ± S.E.M.
Table 1
Locomotor activity in the open ﬁeld after pharmacological treatments.
Experimental groups Number of squares crossed (mean ± SEM)
Acute effect of PPMP
Vehicle 10 mL/kg 148.8 ± 11.03
PPMP 3.7 mg/kg 142.6 ± 14.59
PPMP 7.5 mg/kg 141.4 ± 14.18
PPMP 15 mg/kg 133.8 ± 11.04
PPMP 30 mg/kg 134.7 ± 10.08
PPMP 60 mg/kg 130.9 ± 8.99
IMI 30 mg/kg 133.7 ± 9.42
Chronic effect of PPMP
Vehicle 10 mL/kg 126.5 ± 13.29
PPMP 15 mg/kg 110.6 ± 8.76
FXT 20 mg/kg 138.8 ± 7.39
Interaction of PPMP with PCPA
Vehicle + vehicle 10 mL/kg 150.4 ± 10.00
Vehicle + PPMP 15 mg/kg 159.6 ± 9.93
PCPA 100 mg/kg + Vehicle 141.6 ± 9.01
PPMP 15 mg/kg + PCPA 100 mg/kg 146.8 ± 13.72
Interaction of PPMP with AMPT
Vehicle + vehicle 10 mL/kg 113.4 ± 5.73
Vehicle + PPMP 15 mg/kg 119.8 ± 7.38
AMPT 100 mg/kg + Vehicle 103.8 ± 7.20
PPMP 15 mg/kg + AMPT 100 mg/kg 107.4 ± 6.158
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In order to evaluate the effects elicited by oral administration of
PPMP 15 mg/kg during 14 days, the animals were submitted to the
OFT and FST with an interval of 1 h between the last administration
and behavioral tests. Fluoxetine 20mg/kgwasused as a positive control.
2.3.8. ELISA measurements of BDNF
In order to investigate if PPMP alters the hippocampal concentration
of BDNF, micewere treated once (acute treatment) or for 14-days (p.o.)
with PPMP 15 mg/kg prior to euthanasia and dissection of hippocampi
for BDNF enzyme-linked immunosorbent assay (ELISA). Fluoxetine
20 mg/kg was used as a positive control.
After brain removal (7 per group), the hippocampi were rapidly
dissected, weighed, frozen in liquid nitrogen, and stored at −80 °C.
Hippocampi were suspended (1:40, w:v) in lysis buffer (100 mM
Tris–HCl, 1 mM NaCl, 4 mM EDTA, 2% albumin, 2% Triton-X 100, 0.01%
thimerosal, and protease inhibitors cocktail, pH 7.0) and homogenized
using a Potter homogenizer, with the tube submersed in an ice bath.
Homogenates were centrifuged at 16.800 ×g, 4 °C for 35 min; the
supernatant was used in ELISA. Protein contents were measured
using Bradford's method [17]. BDNF levels were determined using
the BDNF Emax® ImmunoAssay System (Promega, Madison, WI).
ELISA plates were incubated with carbonate coating buffer (containing
monoclonal anti-BDNF) and left overnight at 4 °C. The next day, plates
were blocked with 1× B & S buffer for 1 h at room temperature. Serial
dilutions of known amounts of BDNF ranging from 0 to 500 pg/mL were
performed in duplicate for the standard curve. 100 μL of each sample
was added to each well and incubated for 2 h at room temperature. The
wells were then incubated for 2 h at room temperature with secondary
antihuman BDNF polyclonal antibody prior to incubation with anti-IgY
HRP for 1 h at room temperature. A TMB One Solution® was added to
the wells for 10 min at room temperature to develop color. The reaction
was stopped with the addition of 1 N HCl to the wells. The absorbance
was read at 450 nm within 30 min.
2.3.9. Evaluation of acute toxicity
The toxicity of PPMP was evaluated using in vitro assay of neutral red
in basal line 3T3. Acute oral toxicity was also performed in vivo according
to the recommendations of Organization for Economic Cooperation and
Development (OECD n.423).
2.3.10. Assay of incorporation of neutral red in basal line 3T3
The viability ofmouseﬁbroblasts Balb/c 3T3 cell line (3T3 cells) after
PPMP exposure was evaluated using neutral red dye assay [20,21]. This
test can be used to support dose selection in the evaluation of acute oral
toxicity according to the OECD n.423. For this purpose, the value of IC50
(μg/mL) was used to estimate the LD50 (mg/kg) according to equation
(log (LD50) = 0.435 × log (IC50) + 0.628) as validated by Inter-agency
Coordination Committee on the Validation of Alternative Methods
(ICCVAM) [22]. Tests were performed as previously described [21,22].
2.3.11. Acute oral toxicity evaluation of PPMP
The acute oral toxicity was performed according to the guidelines
recommended in OECD 423 “Acute Oral Toxicity Class” (2001). The
PPMP was prepared in vegetable oil (sunﬂower oil) and administered
orally to Swissmice. This compound was tested twice to estimate the
toxicological risk of PPMP. The animals were fasted for 2 h before evalua-
tion. Animals were observed continuously for 12 h prior to daily observa-
tion up to 14 days record any changes in general behavior or physiological
activities such as consciousness, alertness,motor coordination andmuscle
tone, irritability, touch response, response to the pinching of tail, twisting,
hindquarters position, righting reﬂex, screen grip strength, headset reﬂex,
corneal reﬂex, tremors, Straub's response, anesthesia, lacrimation, ptosis,
piloerection, cyanosis and death [23,24].2.3.12. Statistical analysis
Data are expressed as mean ± standard error of the mean (SEM).
Statistical analyses were performed using Student's t test (control ×
positive control) or by one-way ANOVA followed by Dunnett's test
(control × treated groups). When appropriated, two-way ANOVA
followed by Newman–Keuls' post hoc test. Statistical difference was
set at P b0.05. All graph were drawn using GraphPad Prism version
5.0® software.
3. Results
3.1. Overall effects of PPMP on locomotor activity
All drugs were tested in the OFT in order to avoid false-positive or
false-negative results related to changes in locomotor activity. None of
the treatments in this study altered the locomotor activity of the animals
(Table 1).
3.2. Antidepressant-like effects of acute PPMP treatment
In the FST, PPMP 15 and 30 mg/kg p.o. (P b 0.01 and P b 0.05, respec-
tively, Fig. 1) and imipramine (P b 0.05) reduced the immobility time. In
TST, mice treated with PPMP 3.7 and 7.5 mg/kg p.o. showed a reduction
in immobility time (P b 0.05, Fig. 2). Imipramine also decreased the
immobility time (P b 0.05; Fig. 2).
3.3. Role of serotonergic and catecholaminergic systems in the
antidepressant-like effect of PPMP
Pretreatment with PCPA (5-HT synthesis inhibitor) blocked
antidepressant-like effect of PPMP 15 mg/kg (P b 0.05; Fig. 3A).
Pretreatment with AMPT (non-selective blocker of catecholamine
synthesis) also blocked antidepressant-like effect of PPMP 15 mg/kg
(P b 0.05; Fig. 3B).
3.4. Ex vivo MAO assay
The data on ex vivo assay showed that PPMP did not inhibit MAO
activity. In contrary, positive controls tranylcypromine and clorgyline
in this bioassay inhibited the activity of this enzyme (P b 0.001;
Fig. 1. Acute effects of PPMP on immobility time in the forced swimming test. Data were
expressed as mean ± SEM of 9–12 mice. *P b0.05 and **P b0.01 compared to control
group by one-way ANOVA followed by Dunnett's test (control × treated groups) or Student's
t test (control × positive control). C: control group— vehicle 10 mL/kg p.o., IMI: imipramine
30 mg/kg p.o.
Fig. 3. Acute effects of PPMP after depletion of serotonin with PCPA (100 mg/kg/day, i.p.,
4 days, A) and catecholamines with AMPT (100 mg/kg, i.p., 4 h, B) on immobility time in
the forced swimming test. Data were expressed as mean ± SEM of 10 mice. *P b0.05 com-
pared to control group; and #P b0.05 compared to PPMPgroup by two-wayANOVA followed
by Newman–Keuls' test. C: control group— vehicle 10 mL/kg i.p. + vehicle 10 mL/kg p.o.
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immobility time (P b 0.01, P b 0.001, P b 0.01, respectively; Fig. 4B).
3.5. Antidepressant-like effects in the FST after repeated treatment with
PPMP
Following 14 days of oral treatment, PPMP (15 mg/kg/day) demon-
strated antidepressant-like effect by reducing the immobility time
(P b 0.01; Fig. 5A). The same antidepressant-like effect was observed
with ﬂuoxetine (20 mg/kg/day) treatment (P b 0.01; Fig. 5A).
3.6. ELISA measurements of BDNF
Unlike acute treatment, 14-days treatmentwithPPMP(15mg/kg/day)
increased hippocampal level of BDNF (P b 0.01; Fig. 5C). Similar
result was also observed with ﬂuoxetine treatment (20 mg/kg/day;
P b 0.01; Fig. 5C).
3.7. Evaluation of toxicity
3.7.1. Assay of incorporation of neutral red in basal line 3T3
Exposure of 3 T3 cells to different concentrations of PPMP (0.019–
1.187 mM) resulted in a decline in cell proliferation in a concentration-
dependent manner, with IC50 value of 0.319 mM. From that IC50 value
we estimated in vivo LD50 of 800 mg/kg.
3.7.2. Acute oral toxicity evaluation of PPMP
In the present study, some signs of toxicitywere observed in animals
after administration of PPMP2000mg/kg. In theﬁrst twohours, animalsFig. 2. Acute effects of PPMP on immobility time in the tail suspension test. Data were
expressed as mean ± SEM of 9–10 mice. *P b0.05 compared to control group by one-way
ANOVA followed by Dunnett's test (control × treated groups) or Student's t test (control ×
positive control). C: control group— vehicle 10 mL/kg p.o., IMI: imipramine 30 mg/kg p.o.showed piloerection, ptosis and corporal tremors. Only one animal died
after 48 h of the treatmentwhile others recovered completely from signFig. 4. Effects of PPMP (15 mg/kg), TCP (tranylcypromine 15 mg/kg), and CLG (clorgyline
15mg/kg) on ex vivoMAOassay (A) and immobility time in the forced swimming test (B).
Data were expressed as mean ± SEM of 10 mice. **P b0.01, ***P b0.001 compared to
control group by one-way ANOVA followed by Dunnett's test. C: control group — vehicle
10 mL/kg p.o.
Fig. 5. Effects of PPMP, after repeated treatment, on immobility time (A), as evaluated in
the FST. Datawere expressed asmean±SEMof 9–10mice. Effects of acute (B) and repeated
(C) treatmentwith PPMP (15mg/kg) and Fluoxetine (20mg/kg/day) on hippocampal levels
of BDNF. Data were expressed as mean ± SEM of 5–7 mice. **P b0.01 compared to control
group by Student's t test (control × treated group or control × positive control). C: control
group— vehicle 10 mL/kg p.o., FXT: ﬂuoxetine 20 mg/kg p.o.
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recorded throughout the 14 days of observation.
4. Discussion
In this study, PPMP – a piperazine derivative with putative activities
on CNS – induced antidepressant-like effect inmice. This effect seems to
involve both serotonergic and catecholaminergic systems without inhi-
bition of MAO activity. Repeated treatment with PPMP increased the
level of hippocampal BDNF, thereby suggesting contribution of this
neurotrophic factor to the antidepressant-like effect of this compound.
All drugs were tested in the OFT in order to avoid false-positive
(enhancement of locomotion activity) or false-negative (reduction in
locomotion activity) results [15,25]. None of the treatments used in
this study altered locomotion activity of the animals, thereby suggesting
a speciﬁc antidepressant-like effect of PPMP.
FST and TST are the most widely used behavioral test, because they
are low-costing, time-saving with strong predictive validity to test
potential antidepressants drugs [26–28]. As suggested by Bourin
et al. [25], FST was applied as the ﬁrst behavioral test to investigate
antidepressant-like potential of PPMP.In FST, acute administration of PPMP reduced the immobility
time, suggesting that it has antidepressant-like properties at the
intermediates doses (15 and 30 mg/kg). Like imipramine, male
mice treated with PPMP also showed a reduction in immobility time
in TST, thereby suggesting antidepressant-like effect of this piperazine
derivative.
PPMP effects in FST and TST could be described as U-shaped. The
underlying mechanism of the biphasic dose response observed after
the treatment with PPMP in both models is still unclear. However, this
proﬁle had been observed with some psychoactive drugs independent
of the actionmechanism, type of drug, animalmodel and test conditions.
This pharmacological proﬁle has been described by hormetic dose–
responsemodel [29–33]. Thehormetic dose–responsemayoccur through
the involvement of high and low afﬁnity receptor subsets, in which the
same agonist can elicit a stimulatory or inhibitory response depending
on its concentration [34].
The synthesis of piperazine derivatives seems promising towards
the discovery of new antidepressant drugs. Gautam et al. [7] demonstrat-
ed that treatment with 2-(4-phenylpiperazin-1-yl)-1, 8-naphthyridine-
3-carboxylic acid produced signiﬁcant antidepressant-like effect in
FST and TST. Sapa et al. [6] demonstrated the potent antidepressant-
like activities of several phenylpiperazine pyrrolidin-2-one derivatives
in the FST. Özkay et al. [8] synthesized novel 1-phenyl-2-(4-
substituted-piperazin-1-yl)-propanol derivatives and demonstrated
that some of them possessed antidepressant-like activity in the FST
and TST. Little is known about the mechanism of action of these
piperazinic derivatives. Meanwhile, the monoamines, especially
serotonin, seem to be involved. Gautam et al. [7] suggested that the
antidepressant-like action of 2-(4-phenylpiperazin-1-yl)-1, 8-
naphthyridine-3-carboxylic acid may be mediated by an interaction
with the serotonergic system. In consistence with monoamine
mechanism, Carter et al. [35] has also developed a novel 2-substituted
piperazine-based series of triple (noradrenaline, serotonin and
dopamine) reuptake inhibitors.
In the light of this, pretreatments with PCPA and AMPT are useful
pharmacological approaches to investigate possible role of serotonin
and catecholaminergic systems, respectively, in the mechanism of
action of the antidepressant-like effect of drugs [36–38].
PCPA is an inhibitor of tryptophan hydroxylase, a rate limiting
enzyme in the 5-HT biosynthesis [39], whereas AMPT is an inhibitor of
tyrosine hydroxylase, the rate limiting enzyme in the synthesis of both
noradrenaline and dopamine [40]. Thus, these drugs were used to
deplete 5-HT, and catecholamines levels, respectively. PCPA and AMPT
per se did not affect mice behavior. However, pretreatment with PCPA
and AMPT prevented the behavioral alterations induced by the acute
treatment with PPMP (15 mg/kg). These results suggest involvement
of serotonergic and catecholaminergic systems in the antidepressant-
like effect of PPMP. The involvement of serotonin in the present study
is in agreement with the previous study by Brito et al. [13] who
suggested the participation of serotonergic pathway in the anxiolytic-
like activity of PPMP.
MAO inhibitors have been used for decades as therapeutic options to
treat depression. The mechanisms of antidepressant action of MAO
inhibitors include an increase in brain levels of 5-HT, noradrenaline
and dopamine [41,42]. In order to verify whether the involvement of
serotonergic and catecholaminergic systems is associated with the
inhibition of MAO activity, PPMP effect on the mouse brain MAO
activity was studied. Treatment with PPMP did not cause an inhibi-
tion of MAO activity. Hence, the mechanism of antidepressant-like
effect of PPMP did not involve inhibition of MAO. Although, acute
treatment with PPMP did not inhibit MAO activity, we cannot
exclude the possibility of the inhibition of this enzyme following
chronic treatment with PPMP. Direct interactions with monoaminergic
receptors and/or inhibition of monoamine reuptake are possible mech-
anisms of antidepressant-like effect of PPMP.Meanwhile, there need for
subsequent studies to verify these mechanistic assumptions.
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for 14-days to investigate antidepressant-like effect. Animals treated
with PPMP (15 mg/kg/day) for 14-days displayed antidepressant-like
effect in the FST. The same effect was observed with the 14-days
treatment with ﬂuoxetine 20 mg/kg/day.
The neurotrophic hypothesis of depression suggests that the thera-
peutic activity of some classes of antidepressants (selective serotonin
reuptake inhibitors, noradrenaline selective reuptake inhibitors, MAO
inhibitors, atypical antidepressants) increase the expression of neuro-
trophic factors especially BDNF [3]. BDNF regulates or inﬂuences the
survival and differentiation of adult neural stem cells in the dentate
gyrus of the hippocampus, axon–dendrite differentiation, dendritic
growth, synaptic plasticity [43]. These effects are linked to the cellular
actions observed after the long-term treatment with antidepressants.
With the exception of glutamatergic agents such as ketaminewhich
induce rapid antidepressant-like effect and increased hippocampal
BDNF levels in rats after acute treatment [44], the upregulation of BDNF
is generally dependent on chronic treatment with antidepressant drugs
[45]. Nibuya et al. [45] showed that a signiﬁcant increase in BDNF
mRNA was observed only after chronic administration with several
different antidepressant drugs. This result could explain the time course
for the therapeutic action of classical antidepressants. Similar results
were observed in the present study where PPMP (15 mg/kg/day) and
ﬂuoxetine (20 mg/kg/day) increased the level of hippocampal BDNF
after 14 days of oral treatment.
An in vitro cytotoxicity test provides useful information about the
effect of unknown chemical compounds and may serve as predictors
for in vivo LD50 [21,46]. The cytotoxicity assays with the neutral red
that accumulates in the lysosomes of viable cells, are among the most
sensitive test that detects lysosomal damage in early toxicity [20]. The
estimated IC50 value of 0.319 mM and LD50 was estimated to be
800 mg/kg were reported on PPMP in the present study. However,
there was no information on the toxic effects of the PPMP metabolites.
Despite the in vivo assay indicating an estimated LD50 of
801.98 mg/kg, when mice were treated orally with PPMP, the acute
LD50 was not achieved up to the dose of 2000 mg/kg, being PPMP cate-
gorized as “Class 5” in Globally Harmonized System (GHS), with rel-
atively low acute toxicity, LD50 superior than 2000 mg/kg, a ﬁnding
that may represent a problem to vulnerable population [47], as dem-
onstrate by the signs of toxicity. These results are in accordance with
Brito et al. [13] that reported PPMP-induced convulsions at the dose
of 1.1 mmol/kg (approximately 330 mg/kg) without any death in male
mice. It is noteworthy that the doses used in the present study were
lower than the LD50 or the dose that induced signs of toxicity.5. Conclusions
In conclusion, PPMPelicits anantidepressant-like effect that probably
involves both serotonergic and catecholaminergic systems without any
inhibition ofMAO activitywhile repeated treatmentwith this piperazine
derivative increases hippocampal level of BDNF. Altogether, these data
suggest changes in synaptic plasticity after long-term treatment as the
underlying mechanism of the antidepressant-like effect of PPMP.Conﬂict of interest statement
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